Search Results - "GALLEN, Manuel"

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer by Montagut, Clara, Dalmases, Alba, Bellosillo, Beatriz, Crespo, Marta, Pairet, Silvia, Iglesias, Mar, Salido, Marta, Gallen, Manuel, Marsters, Scot, Tsai, Siao Ping, Minoche, André, Seshagiri, Somasekar, Serrano, Sergi, Himmelbauer, Heinz, Bellmunt, Joaquim, Rovira, Ana, Settleman, Jeff, Bosch, Francesc, Albanell, Joan

“…By modeling acquired resistance to the EGFR antibody cetuximab in metastatic colorectal cancer, the authors identify a new mutation in the ectodomain of the…”
Get full text

Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study by FERNANDEZ-MARTOS, Carlos, PERICAY, Carles, MENGUAL, Jose Luis, SAIGI, Eugenio, ESTEVAN, Rafael, MIRA, Moises, POLO, Sonia, HERNANDEZ, Ana, GALLEN, Manuel, ARIAS, Fernando, SERRA, Javier, ALONSO, Vicente, APARICIO, Jorge, SALUD, Antonieta, SAFONT, Mariajose, MASSUTI, Bertomeu, VERA, Ruth, ESCUDERO, Pilar, MAUREL, Joan, MARCUELLO, Eugenio

“…PURPOSE The optimal therapeutic sequence of the adjuvant chemotherapy component of preoperative chemoradiotherapy (CRT) for patients with locally advanced…”
Get full text

First‐Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single‐Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study by Díaz‐Rubio, Eduardo, Gómez‐España, Auxiliadora, Massutí, Bartomeu, Sastre, Javier, Abad, Albert, Valladares, Manuel, Rivera, Fernando, Safont, Maria J., Martínez de Prado, Purificación, Gallén, Manuel, González, Encarnación, Marcuello, Eugenio, Benavides, Manuel, Fernández‐Martos, Carlos, Losa, Ferrán, Escudero, Pilar, Arrivi, Antonio, Cervantes, Andrés, Dueñas, Rosario, López‐Ladrón, Amelia, Lacasta, Adelaida, Llanos, Marta, Tabernero, Jose M., Antón, Antonio, Aranda, Enrique

“…Purpose. The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus…”
Get full text

Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First‐Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study by Sastre, Javier, Maestro, M. Luisa, Gómez‐España, Auxiliadora, Rivera, Fernando, Valladares, Manuel, Massuti, Bartomeu, Benavides, Manuel, Gallén, Manuel, Marcuello, Eugenio, Abad, Albert, Arrivi, Antonio, Fernández‐Martos, Carlos, González, Encarnación, Tabernero, Josep M., Vidaurreta, Marta, Aranda, Enrique, Díaz‐Rubio, Eduardo

“…Background. The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single‐agent bevacizumab versus bevacizumab…”
Get full text

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial by Becerra, Carlos R., Salazar, Ramon, Garcia-Carbonero, Rocio, Thomas, Anne L., Vázquez-Mazón, Federico J., Cassidy, James, Maughan, Tim, Castillo, Manuel Gallén, Iveson, Tim, Yin, Donghua, Green, Stephanie, Bergsland, Emily K.

“…Purpose Figitumumab (CP-751,871) is a human IgG2 monoclonal antibody that binds and down-regulates insulin-like growth factor receptor-1 (IGF-1R) and inhibits…”
Get full text

Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial by Fernandez-Martos, Carlos, Estevan, Rafael, Salud, Antonia, Pericay, Carles, Gallen, Manuel, Sierra, Enrique, Serra, Javier, Pera, Miguel, Maurel, Juan, Delgado, Salvadora, Safont, M. José, Roig, Jose Vicente, Aparicio, Jorge, Feliu, Jaime, Garcia, Damian, Vera, Ruth, Suarez, Javier, Alonso, Vicente, Martin-Richard, Marta, Brown, Gina

“…Abstract only 3586 Background: Retrospective data suggest that RT might not be needed in all patients with stage II/III RC. Modern systemic therapy might have…”
Get full text

Time from (clinical or certainty) diagnosis to treatment onset in cancer patients: the choice of diagnostic date strongly influences differences in therapeutic delay by tumor site and stage by Macià, Francesc, Pumarega, José, Gallén, Manuel, Porta, Miquel

“…Abstract Objectives To analyze whether differences between the interval from suspicion or clinical diagnosis to treatment onset (IClinDT) and the interval from…”
Get full text

Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function by Morales-Barrera, Rafael, Bellmunt, Joaquim, Suárez, Cristina, Valverde, Claudia, Guix, Marta, Serrano, Cesar, Gallén, Manuel, Carles, Joan

“…Abstract Background Cisplatin-based combination chemotherapy is the mainstay of treatment for locally advanced or metastatic urothelial carcinoma. However,…”
Get full text

Stage II disease, elderly patients, secondary neoplasms, and the MOSAIC trial by Gallén, Manuel, Gallego, Rosa, Bellmunt, Joaquim

Get full text

Colorectal cancer survival: results from a hospital-based cancer registry by Agüero, Fernando, Murta-Nascimento, Cristiane, Gallén, Manuel, Andreu-García, Montserrat, Pera, Miguel, Hernández, Cristina, Burón, Andrea, Macià, Francesc

“…colorectal cancer is one of the most common malignancies in developed countries. Data on specific and 10-year survival are scarce. This study analyzes overall…”
Get full text

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX by Dimet, Stéphanie, Bennouna, Jaafar, Laurent-Puig, Pierre, Thaler, Josef, Samonigg, Hellmut, Schmid, Franz, Steger, Günther, Lang, Alois, Fridrik, Michael, Woell, Ewald, Kerger, Joseph, Deboever, Guido, Polus, Marc, Delaunoit, Thierry, Peeters, Marc, Janssens, Jos, Van Laethem, Jean-Luc, Nielsen, Svend Erik, Bennouna-Louridi, Jaafar, Ychou, Marc, Miglianico, Laurent, Rougier, Philippe, Merrouche, Yacine, Ramee, Jean-Francois, Garnier, Claire, Lecaille, Cedric, Andre, Thierry, Laplaige, Philippe, Bedenne, Laurent, Coriat, Romain, Dupuis, Olivier, Fruge, Frederic, Lecomte, Thierry, Lam, You-Heng, Catteau, Sylviane, Codoul, Jean-Francois, Provencal, Jocelyne, Desir, Jean-Paul, Hartwig, Johannes, Krummel, Yves, Budnik, Tamara Matysiak, Palascak-Juif, Vanessa, Darut-Jouve, Ariane, Wendehenne, Frederic, Matzdorff, Axel, Mueller, Lothar, Hoehler, Thomas, Asperger, Walter, Kroening, Hendrik, Groschek, Matthias, Ziegenhagen, Nicolas, von Wichert, Goetz, Schmidt, Karl-Heinz, Vehling-Kaiser, Ursula, Holtkamp, Wilhelm, Schmoll, Hans-Joachim, Denzlinger, Claudio, Caca, Karel, Eschenburg, Henning, Mueller, Sebastian, Wagner, Siegfried, Aprile, Giuseppe, Martoni, Andrea, Passalacqua, Rodolfo, Tamberi, Stefano, Verusio, Claudio, Marzola, Marina, Boni, Corrado, Vaghi, Massimo, Cruciani, Giorgio, Di Costanzo, Francesco, Petrioli, Roberto, Alabiso, Oscar, Corsi, Domenico Cristi, Chiara, Silvana, Ferraù, Francesco, Mellidez, Juan Carlos, Freire, Joao, Sarmento, Cristina, Santo, Jorge Espirito, Monteiro, Amélia, Tabernero, Josep, Gil, Silvia, Esteve, Albert Abad, Gallego, Javier, Pericay, Carlos Pijaume, Figueiras, Manuel Constenla, Garcia, Amelia Lopez-Ladron, Garcia-Ramos, Antonio Arrivi, Gaspar, Eugenio Marcuello, Lopez, Jose Garcia, Morales, Monica Guillot, Ruiz, Teresa Checa, Aliguer, Miquel Nogue, de Taranco, Amalia Velasco Ortiz, Gaspa, Ferran Losa, Ponce, Jose Juan, Martinez, Jose Ales, Ruiz, Margarita Centelles, Glynne-Jones, Rob

“…The prognostic value of lymphocyte infiltration (LI) of colorectal carcinoma (CC) has been demonstrated by several groups. However, no validated test is…”
Get full text

Symptom-to-diagnosis interval and survival in cancers of the digestive tract by Fernandez, Esteve, Porta, Miquel, Malats, Núria, Belloc, Josep, Gallén, Manuel

“…The objective was to identify the main correlates of the symptom-to-diagnosis interval (SDI) and to analyze their influence upon the survival in patients with…”
Get full text

Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab by Sastre, Javier, Vidaurreta, Marta, Gómez, Auxiliadora, Rivera, Fernando, Massutí, Bartomeu, López, Margarita Reboredo, Abad, Albert, Gallen, Manuel, Benavides, Manuel, Aranda, Enrique, Rubio, Eduardo Díaz

“…Micro-Abstract This is a post hoc analysis of biomarkers from a phase III clinical trial in metastatic colorectal cancer. Circulating tumor cell count and…”
Get full text

Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients by Abad, Albert, Vieitez, Jose M, Alonso, Vicente, Garcia Alfonso, Pilar, Manzano, Jose Luis, Massuti, Bartomeu, Benavides, Manuel, Carrato, Alfredo, Remon, Jordi, Gallego Plazas, Javier, Conde, Veronica, Gravalos Castro, Cristina, Valladares, Manuel, Provencio, Mariano, Salazar, Ramon, Gallen, Manuel, Rivera, Fernando, Sastre, Javier, Aranda, Enrique, Martinez-Balibrea, Eva

“…Abstract only…”
Get full text

Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer by Pericay Pijaume, Carles, Escudero Emperador, Pilar, Bastús Piulats, Román, Campos Cervera, Juan Manuel, Esquerdo Galiana, Gaspar, Gallén Castillo, Manuel, Alfaro Gamero, Jordi, Dotor Navarro, Emma, Pisa Gatell, Aleydis, Guasch Jordán, Inmaculada, Saigí Grau, Eugeni

“…Aim Advanced pancreatic cancer has a bad prognosis, with a median overall survival (OS) no longer than 4–6 months. Since the end of last century, monotherapy…”
Get full text

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer by Montagut, Clara, Dalmases, Alba, Bellosillo, Beatriz, Crespo, Marta, Pairet, Silvia, Iglesias, Mar, Salido, Marta, Gallen, Manuel, Marsters, Scot, Tsai, Siao Ping, Minoche, André, Somasekar, Seshagiri, Serrano, Sergi, Himmelbauer, Heinz, Bellmunt, Joaquim, Rovira, Ana, Settleman, Jeff, Bosch, Francesc, Albanell, Joan

Get full text

Preoperative Bevacizumab, Capecitabine and Oxaliplatin (CAPOX-B) in Intermediate Risk Rectal Adenocarcinoma, Selected by High Resolution MRI. Gemcad 0801 Study by Carlos, Fernandez-Martos, Gallen, Manuel, Salud, Antonieta, Pericay, Carles, Maurel, Joan, Safont, Maria Jose, Aparicio, Jorge, Feliu, Jaime, Vera, Ruth, Alonso-Orduna, Vicente, Gallego, Javier, Martin, Marta, Estevan, Rafael, Brown, Gina

Get full text

Erratum: Corrigendum: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer by Montagut, Clara, Dalmases, Alba, Bellosillo, Beatriz, Crespo, Marta, Pairet, Silvia, Iglesias, Mar, Salido, Marta, Gallen, Manuel, Marsters, Scot, Tsai, Siao Ping, Minoche, André, Somasekar, Seshagiri, Serrano, Sergi, Himmelbauer, Heinz, Bellmunt, Joaquim, Rovira, Ana, Settleman, Jeff, Bosch, Francesc, Albanell, Joan

Get full text

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset by Gaenzer, Johannes, Schmid, Franz, Steger, Günther, Andel, Johannes, Hofbauer, Friedrich, Woell, Ewald, Prager, Manfred, Goeminne, Jean Charles, Vergauwe, Philippe, Janssens, Jos, Schrijvers, Dirk, Van Daele, Daniel, Ychou, Marc, Zawadi, Mohamed-Ayman, Bouche, Olivier, Pezet, Denis, Desseigne, Francoise, Ducreux, Michel, Levache, Charles-Briac, Merrouche, Yacine, Ellis, Stephen, Ramee, Jean-Francois, Chauffert, Bruno, Borel, Christian, Seitz, Jean-Francois, Smith, Denis, Andre, Thierry, Vanoli, Andre, Aparicio, Thomas, Laplaige, Philippe, Coriat, Romain, Geoffroy, Patrick, Piot, Gilles, Sobhani, Iradej, Asnacios, Amani, Galais, Marie-Pierre, Gargot, Dany, Legoux, Jean-Louis, Goldfain, Denis, Verge, Denis Pere, Provencal, Jocelyne, Desir, Jean-Paul, Fallik, David, Garcia, Bruno, Genet, Dominique, MatysiakBudnik, Tamara, Palascak-Juif, Vanessa, Randrianarivelo, Harizo, Aleba, Albert, Hoehler, Thomas, Asperger, Walter, Kroening, Hendrik, Fuxius, Stefan, Groschek, Matthias, Denzlinger, Claudio, GuenterDerigs, Hans, Becker-Boost, Ingulf, Constantin, Christian, Decker, Thomas, Eschenburg, Henning, Gabius, Sigrun, Hebart, Holger, Hoffmeister, Albrecht, Wagner, Siegfried, Daum, Severin, Heinemann, Volker, Labianca, Roberto, Colucci, Giuseppe, Zaniboni, Alberto, Pasquini, Enzo, Rabbi, Carla, Barone, Carlo, Verusio, Claudio, Marzola, Marina, Vaghi, Massimo, Cruciani, Giorgio, Aglietta, Massimo, Chiara, Silvana, Sanches, Evaristo, Mellidez, Juan Carlos, Freire, Joao, Guedes, Fátima, Monteiro, Amélia, Sa, Anabela, Tabernero, Josep, Herrero, Fernando Rivera, Valera, Javier Sastre, Gil, Silvia, Orduña, Vicente Alonso, Garcia, Ruth Vera, Remon, Jordi, Cervantes, Andres, Martos, Carlos Fernandez, Montero, Ines Cabezas, Flores, Encarnacion Gonzalez, LacastaMuñoa, Adelaida, Gaspa, Ferran Losa, Roig, Carlos Bosch, Jimenez, Pedro Valero, Glynne-Jones, Rob

Get full text

Correction: Corrigendum: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer by Montagut, Clara, Dalmases, Alba, Bellosillo, Beatriz, Crespo, Marta, Pairet, Silvia, Iglesias, Mar, Salido, Marta, Gallen, Manuel, Marsters, Scot, Tsai, Siao Ping, Minoche, André, Somasekar, Seshagiri, Serrano, Sergi, Himmelbauer, Heinz, Bellmunt, Joaquim, Rovira, Ana, Settleman, Jeff, Bosch, Francesc, Albanell, Joan

“…Nat. Med. 18, 221–223 (2012); published online 22 January 2012; corrected after print 6 July 2012 In the version of this article initially published, due to an…”
Get full text